1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
JW Pharmaceutical Corporation

JW Pharmaceutical Corporation

49,750.00
KRW
-150.00
(-0.30%)
Nov 18Next Earn
JW Pharmaceutical Corporation
KRX:001067
(Korea Stock Exchange)

Recent

price

49,750.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
443,276
431,007
397,085
394,182
412,791
434,352
467,465
502,919
537,182
511,335
547,336
606,585
684,351
748,527
719,376
775,298
820,862
Sales/Revenue/Turnover
6.58
3.82
2.39
6.57
3.21
4.96
5.25
4.32
4.02
-3.72
-0.24
5.14
9.17
13.48
11.5
12.18
13.94
Operating Margin (%)
9,038
12,840
14,359
16,153
16,617
17,863
18,646
18,789
17,682
20,349
20,688
16,112
16,836
22,575
19,101
18,748
19,492
Depreciation Expense
5,600
-9,804
-20,394
2,275
-2,357
1,961
-10,934
-742
8,057
-25,275
-15,241
-968
31,892
37,006
65,040
61,511
101,281
Net Income, GAAP
37.27
- -
- -
33.21
- -
4.63
254.4
- -
21.28
- -
- -
107.02
34.19
29.92
21.09
30.76
12.16
Effective Tax Rate (%)
1.26
-2.27
-5.14
0.58
-0.57
0.45
-2.34
-0.15
1.5
-4.94
-2.78
-0.16
4.66
4.94
9.04
7.93
12.34
Profit Margin (%)
115,536
84,648
34,046
7,815
132,065
115,393
164,666
136,830
145,542
57,074
64,581
83,774
45,326
91,164
97,798
87,353
123,858
Working Capital
179,361
165,042
124,216
52,589
132,496
100,553
49,404
13,500
47,189
31,646
74,905
122,070
1,849
52,876
45,974
18,454
17,376
LT Debt
188,583
170,251
163,663
200,739
220,024
225,407
276,313
270,777
260,111
230,092
207,467
188,540
225,759
265,440
329,487
369,370
409,936
Total Equity
4.33
- -
- -
3.41
- -
4.2
-7.85
- -
3.98
- -
- -
-0.57
10.28
17.64
16.35
16.43
23.9
Return on Invested Capital (%)
3.81
- -
- -
3.1
- -
3.07
-5.9
- -
3.32
- -
- -
-0.25
9.23
10.19
17.03
15.28
22.62
Return on Capital (%)
2.98
-5.48
-12.25
1.25
-1.13
0.89
-4.39
-0.27
3.07
-10.45
-7.07
-0.48
14.69
14.87
22.16
17.81
27.93
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
36,181
36,154
54,374
LT Borrowings
- -
- -
- -
LT Finance Leases
18,454
17,971
17,376
Preferred Equity and Hybrid Capital
4,039
4,039
4,039
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
296,512
308,895
344,501
Cash, Cash Equivalents & STI
61,341
66,319
102,084
Accounts Receivable, Net
114,573
115,158
117,806
Inventories
109,897
114,739
111,652
Total Current Liabilities
209,159
211,353
220,643
Payables & Accruals
- -
- -
- -
ST Debt
36,181
36,154
54,374
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.97%
12.89%
12.1%
Free Cash Flow
-6.22%
138.76%
17.6%
Net Income, GAAP
-579.16%
-680.48%
-5.43%
Sales/Revenue/Turnover
6.12%
7.38%
7.77%
Total Cash Common Dividend
16.63%
9.94%
14.52%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
180,594
172,276
178,655
187,851
719,376
2025
185,236
191,105
200,016
198,941
775,298
2026
199,885
222,020
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
JW Pharmaceutical Corporation JW Pharmaceutical Corporation (001060.KS) manufactures and markets pharmaceuticals, medical supplies, and healthcare products primarily focused on hospital and consumer markets in South Korea and internationally. Founded in 1945 and headquartered in Gwacheon-si, South Korea, the company operates across therapeutic areas including cancer, immunological diseases, cardiovascular and metabolic disorders, regenerative medicine, eye diseases, pancreatic cancer, antibiotics, infusion therapies, wound care, pain management, and beauty care; its core branded products encompass original pipelines such as Livalo (pitavastatin for hypercholesterolemia), Thrupas, Sigmart, Actemra, Winuf (third-generation three-chamber nutrient infusion with omega-3 and omega-6), Iminefem (next-generation carbapenem antibiotic first generic), JWELRY, WNT/β-catenin inhibitors, CLOVER platform therapies, G-CSF for neutropenia, Himom care bands, Hwacol cold medicine, Frenz Eye Drops, Changpo(n) premium hair dye, low-protein relief foods for kidney patients, and localized medical devices like digital X-rays, incubators, operating tables, and examination tables acquired via JW Bioscience in 2023. JW Pharmaceutical Corporation maintains global R&D networks including C&C Research Laboratories, JW Theriac in the US, and advanced manufacturing at facilities like JW Dangjin production complex and Sihwa factory compliant with international GMP standards, serving business-to-business and consumer segments with approximately 1,068 employees. Recent developments include expanded collaborations in 2025 with Regeneron via JW Therapeutics for TCR-T cell therapies and platform innovations in oncology, a May 2024 joint research agreement with Oncocross employing AI-driven RAPTOR platform for new indications in anticancer and regenerative medicines, and a October 2024 partnership with Tempus leveraging real-world data and AI for precision medicine advancements; these alliances underscore strategic shifts toward AI integration, cell therapies, and global innovative drug pipelines while enhancing clinical development efficiency.